Carfilzomib

• Background:

  Carfilzomib / PR-17 is an irreversible proteasome inhibitor that targets the chymotrypsin-like beta5 subunit of 20S proteasome. It can arrest the cell cycle and trigger apoptosis in tumor cell lines.

• Description:

  20S Proteasome inhibitor

• Product Name Alternative:

  (αS) -α-[[2- (4-morpholinyl) acetyl]amino]benzenebutanoyl-L-leucyl-N-[ (1S) -3-methyl-1-[[ (2R) -2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide, PR-17, Carfilzomib, Kyprolis, Carfilzomib (PR-171), PR-171, UNII-72X6E3J5AR

• UNSPSC:

  41116105

• Type:

  Inhibitor

• Source:

  Synthetic

• Field of Research:

  Cancer | Cancer Growth Inhibitors | Proteasome Inhibitors

• Purity:

  >98% (TLC) ; NMR (Conforms)

• Weight:

  0.025

• Format:

  White powder

• Solubility:

  Soluble in DMSO (80 mg/ml), or ethanol (25 mg/ml)

• Molecular Formula:

  C40H57N5O7

• Molecular Weight:

  719.9

• Precautions:

  Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

• CAS Number:

  868540-17-4